Chemotherapy News and Research

Latest Chemotherapy News and Research

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

Breast cancer patients with BRCA1 mutation experience pCR after neoadjuvent chemotherapy

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

7 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Researchers discover why tumors evolve

Like snakes, tumour cells shed their skin. Cancer is not a static disease but during its development the disease accumulates changes to evade natural defences adapting to new environmental circumstances, protecting against chemotherapy and radiotherapy and invading neighbouring organs, eventually causing metastasis.

3 Sep 2011

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years and 75 percent in patients who were in remission at the time of the transplant.

2 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

More strides against childhood cancer

The treatment of childhood cancer is one of the great success stories of modern medicine. A few decades ago, only 20 percent of children survived the disease. Today, overall survival rates approach 80 percent. Yet cancer remains the leading cause of death from disease in U.S. children older than 1 year of age, and some types of pediatric cancer continue to have poor survival rates.

2 Sep 2011

New implantable micro oxygen generator improves effectiveness of anticancer tharapy

Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.

2 Sep 2011

Valproic acid may increase survival for brain tumor patients

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures.

2 Sep 2011

Fibrous stroma can help predict aggressiveness of squamous cell carcinoma

The nature of the connective tissue surrounding lung cancer nests can help predict the aggressiveness of squamous cell carcinoma, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

Viewpoints: States' anti-abortion laws; unproven cancer therapy; paying for retirees' health benefits

Since last year, 13 states, including Kansas, have enacted laws banning insurance coverage of abortion in the health insurance exchanges created by the federal health care reform law. Some states have gone even further, aggressively restricting abortion coverage even in private insurance plans sold outside the exchanges. ... These cases, some of which are being appealed, are testing whether the antiabortion movement will get its way. It shouldn't.

31 Aug 2011

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Radiation can make cancer cells resistant to radio- and chemotherapy. University of Oslo researchers have now figured out how resistance can be switched on and off.

30 Aug 2011

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer.

30 Aug 2011

U-M offers transplantation for patients with bile duct cancer

Robert "Buzz" Gehle thought the itchy rash he was experiencing was a recurrence of an earlier case of shingles. But when his doctor saw he was also jaundiced, he immediately knew there was a problem with Gehle's liver.

30 Aug 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Medical engineers develop sensor chip to monitor cancerous tumors

A surgery is usually one of the first therapy options in cancer treatment. However, some tumors, such as brain tumors, can be difficult to operate on if there is a risk of damaging surrounding nerve tissue.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

Breast cancer patients with BRCA1 mutation experience pCR after neoadjuvent chemotherapy

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Researchers discover why tumors evolve

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

More strides against childhood cancer

New implantable micro oxygen generator improves effectiveness of anticancer tharapy

Valproic acid may increase survival for brain tumor patients

Fibrous stroma can help predict aggressiveness of squamous cell carcinoma

Viewpoints: States' anti-abortion laws; unproven cancer therapy; paying for retirees' health benefits

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

U-M offers transplantation for patients with bile duct cancer

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Medical engineers develop sensor chip to monitor cancerous tumors

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in